Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Face Mask Shortages Crippling Drug Makers’ Business Activities, Travel Restrictions Could Delay Approval
March 26, 2020
- Aspen Japan President to Lead Sandoz K.K.
March 26, 2020
- Boehringer Ingelheim Recalling Alesion after Impurities Detected
March 25, 2020
- Astellas Inks Biotech R&D Pact for Next-Gen I/O Therapy
March 25, 2020
- AnGes Now Ready to Launch Preclinical Study for Coronavirus DNA Vaccine
March 25, 2020
- Nippon Chemiphar Snaps Up Japan Rights for Tumor Microenvironment Therapy from Delta-Fly
March 25, 2020
- Novartis Japan to Shed Oncology Staffers amid Overall Downscaling
March 24, 2020
- Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
- Chugai, Roche, Genentech File Patent Suit against Fresenius Kabi over Alecensa
March 24, 2020
- KM Biologics, Takeda to Wind Up Sales Partnership on Flu Vaccine
March 24, 2020
- Mochida, Gene Techno Science Pair Up for Regenerative Medicines for Rare Gastrointestinal Diseases
March 24, 2020
- Takeda’s Entyvio Approved in China
March 24, 2020
- Kitasato Institute Embarks on Drug Screening Project for COVID-19
March 23, 2020
- Oncolys to Create US Non-Clinical Research Subsidiary, Accelerating Drug R&D
March 23, 2020
- Eiken’s Novel Coronavirus Detection Reagent Kit Bags Public Insurance Coverage
March 23, 2020
- Asahi Kasei Grabs Global Rights for SBI Biotech’s Autoimmune Disease Therapy
March 23, 2020
- Fujifilm to Scale Up Production Capacity at UK Subsidiary with 9 Billion Yen Investment
March 23, 2020
- (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
- Nipro Confirms Second Coronavirus Case, Again in Niigata
March 19, 2020
- RIMD, BIKEN, NIBIOHN Start Development of COVID-19 Vaccine/Test Technology
March 19, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…